Skip to main content
S&P 5007,718.60-0.38%DOW53,414.25-0.51%NASDAQ26,506.99-0.29%BTC$79,656.00-1.71%ETH$2,454.45-1.99%GOLD$4,477.20-1.38%OIL$91.22-0.09%
Smart Investors Daily
Integra LifeSciences Holdings Corporation logo

NASDAQ · IART

Integra LifeSciences Holdings Corporation

Healthcare · Medical - Devices

$16.72

Up+$0.28 (+1.70%)

Updated Sep 6, 2026, 4:49 AM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.1B
P/E ratio
-2.18
Dividend yield
0.00%
52-week range
$8.70 – $20.49
Volume
674.91K
Avg. volume
1.05M

Price performance

IART price history

1M range · 0 trading sessions · Daily adjusted prices

IART does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest IART news

The latest Smart Investors Daily articles mentioning IART.

Stock researchCompany · Overview

IART research

Overview

Company profile and research snapshot.

Company profile

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
IART recent ratings
DateFirmRatingTarget
Jul 30, 2026Wells FargoEqual-Weight—
Jul 28, 2026UBSNeutral—
Jul 16, 2026Truist SecuritiesHold—
Jul 9, 2026BMO CapitalMarket Perform—
Jul 8, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 3, 2026

Integra LifeSciences Holdings (IART) Returns To Profit As Fair Value Debate Stays In Focus

Integra LifeSciences Holdings earnings and guidance draw investor focus Integra LifeSciences Holdings (IART) has come back into focus after reporting second quarter 2026 results with a swing back to profitability, while also updating quarterly and full year revenue guidance on July 29. The company reported second quarter sales of US$418.76 million compared with US$415.61 million a year earlier. Net income was US$4.48 million compared with a net loss of US$484.07 million in the prior year...

Yahoo · Aug 2, 2026

Why Integra LifeSciences (IART) Trimmed Its 2026 Outlook After Returning to Profitability

Integra LifeSciences Holdings reported past second-quarter 2026 results with sales of US$418.76 million and net income of US$4.48 million, and issued third-quarter revenue guidance of US$410 million to US$425 million while slightly trimming its full-year 2026 outlook to US$1.65 billion to US$1.70 billion due to currency effects. The swing from a very large prior-year net loss to a modest profit, while maintaining overall revenue guidance, points to meaningful operational and earnings quality...

Yahoo · Aug 1, 2026

IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By